FrancophonIA/ELRC3.0 huggingface dataset:
English: In a clinical trial of high-risk post acute coronary syndrome patients, characterised by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH (International Society on Thrombosis and Haemostasis) major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year).
Croatian: U kliničkom ispitivanju u visokorizičnih bolesnika nakon akutnog koronarnog sindroma, karakteriziranog višestrukim srčanim i nesrčanim popratnim bolestima, koji su primili ASK ili kombinaciju ASK-a i klopidogrela, prijavljen je značajan porast rizika od velikog krvarenja prema Međunarodnom društvu za trombozu i hemostazu (engl.
English: VTE, VTE-related death, or major bleeding
Croatian: VTE ili smrtni ishod povezan s CV VTE, smrtni ishod povezan s VTE, ili veliko krvarenje
English: Warfarin N=9,081 n (%/yr)
Croatian: Varfarin N=9081 n (% na godinu)
English: ASA N = 2,780 n (%/year)
Croatian: ASK N = 2780 n (% na godinu)
English: 5 mg twice daily
Croatian: 5 mg dva puta na dan
English: The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study.
Croatian: U ispitivanju ARISTOTLE ukupna stopa prekida liječenja zbog nuspojava bila je 1,8% za apiksaban i 2,6% za varfarin.
English: - Bleeding: - in your lungs or your throat - into the space behind your abdominal cavity - into a muscle
Croatian: - Krvarenje: - u plućima ili grlu - u prostoru iza trbušne šupljine - u mišić
English: Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and Cmax, respectively.
Croatian: Istodobna primjena apiksabana i rifampicina, snažnog induktora CYP3A4 i P-gp-a, smanjila je srednju vrijednost AUC-a apiksabana za 54%, a vrijednost Cmax za 42%.
English: To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.
Croatian: Sprječavanje nastanka krvnog ugruška u srcu u bolesnika s nepravilnim otkucajima srca u kojih postoji još barem jedan dodatan čimbenik rizika.
English: Each tablet contains 2.5 mg of apixaban.
Croatian: Jedna tableta sadrži 2,5 mg apiksabana.
English: Each tablet contains 5 mg of apixaban.
Croatian: Jedna tableta sadrži 5 mg apiksabana.
English: ASA N = 2,791 n (%/year)
Croatian: ASK N = 2791 n (% na godinu)
English: Immune system disorders Hypersensitivity, allergic oedema and Anaphylaxis
Croatian: Poremećaji imunološkog sustava Preosjetljivost, alergijski edem i anafilaksija manje često manje često
English: In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions.
Croatian: U ispitivanjima prevencije venskih tromboembolijskih događaja nuspojave su se javile u ukupno 11% bolesnika liječenih apiksabanom u dozi od 2,5 mg dvaput na dan.
English: Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban Cmax.
Croatian: Istodobna primjena apiksabana s ketokonazolom (400 mg jedanput na dan), snažnim inhibitorom CYP3A4 i P-gp-a, udvostručila je srednju vrijednost AUC-a apiksabana i dovela do porasta prosječnog Cmax apiksabana za 1,6 puta.
English: - Bleeding: - into a muscle - in your eyes - from your gums and blood in your spit when coughing - from your rectum - Hair loss
Croatian: - Krvarenje: - u mišiću - u očima - iz desni i krv u ispljuvku kod iskašljavanja - iz završnog dijela debelog crijeva - Gubitak kose
English: Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or Cmax.
Croatian: Istodobna primjena jedne doze apiksabana (10 mg) i jedne doze naproksena (500 mg), često korištenog NSAIL-a, nije utjecala na AUC ni Cmax naproksena.
English: - Unit dose blisters in cartons of 100 x 1 film-coated tablets for delivery in hospitals are also available.
Croatian: - Dostupni su blisteri s jediničnim dozama sa 100 x 1 filmom obloženom tabletom za primjenu u bolnicama.
English: • diabetes mellitus
Croatian: • šećerna bolest
English: Cartons of 14, 20, 28, 56, 60, 168 and 200 film-coated tablets.
Croatian: Pakiranja sa 14, 20, 28, 56, 60, 168 i 200 filmom obloženih tableta.
English: The recommended dose is one tablet of Eliquis 5 mg twice a day.
Croatian: Preporučena doza je jedna Eliquis 5 mg tableta dvaput na dan.
English: • Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.
Croatian: • Pažljivo prenesite sav prašak u odgovarajuću posudu, a zatim pomiješajte prašak s malo, npr.
English: An agent to reverse the anti-factor Xa activity of apixaban is available.
Croatian: Dostupan je lijek za reverziju anti-faktor Xa aktivnosti apiksabana.
English: NAME OF THE MARKETING AUTHORISATION HOLDER Bristol-Myers Squibb/Pfizer EEIG
Croatian: Bristol-Myers Squibb/Pfizer EEIG
English: The film-coated tablets are yellow, round and marked with “893” on one side and “2½” on the other side.
Croatian: Okrugle filmom obložene tablete žute boje s oznakom "893" s jedne i "2½" s druge strane.
English: Eye haemorrhage (including conjunctival haemorrhage)
Croatian: Krvarenje u oku (uključujući krvarenje u konjunktive)
English: Your doctor needs to do blood-measurements and instruct you when to start taking Eliquis.
Croatian: Prestanite uzimati lijek koji sadrži antagonist vitamina K. Liječnik Vam mora napraviti krvnu pretragu i reći kada trebate početi uzimati Eliquis.
English: Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding.
Croatian: Dok dojite, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.
English: In patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).
Croatian: U bolesnika s klirensom kreatinina < 15 ml/min, ili u bolesnika na dijalizi, nema kliničkog iskustva stoga se primjena apiksabana ne preporučuje (vidjeti dijelove 4.4 i 5.2).
English: - Film coat: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin, red iron oxide (E172).
Croatian: Film ovojnica: laktoza hidrat hipromeloza (E464) titanijev dioksid (E171) triacetin željezov oksid, crveni (E172)
English: The efficacy results for prespecified subgroups, including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial.
Croatian: Rezultati djelotvornosti za unaprijed određene podskupine, uključujući podskupine s obzirom na rezultat na ljestvici CHADS2, dob, tjelesnu težinu, spol, status bubrežne funkcije, pretrpljen moždani udar ili tranzitornu ishemijsku ataku i šećernu bolest, bili su u skladu s primarnim rezultatima djelotvornosti u cjelokupnoj populaciji obuhvaćenoj ispitivanjem.
English: Cartons of 10, 20, 60, 168 and 200 film-coated tablets.
Croatian: Kutije sa 10, 20, 60, 168 i 200 filmom obloženih tableta.
English: In patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).
Croatian: U bolesnika s klirensom kreatinina < 15 ml/min, ili u bolesnika na dijalizi, nema kliničkog iskustva stoga se primjena apiksabana ne preporučuje (vidjeti dijelove 4.2 i 5.2).
English: - for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).
Croatian: - u prevenciji VTE kod elektivnog kirurškog zahvata ugradnje endoproteze kuka ili koljena (VTEp), u liječenju DVT, u liječenju PE i u prevenciji ponavljajućih DVT i PE (VTEt), nije potrebno prilagođavati dozu (vidjeti dio 5.2);
English: In individuals with mild (creatinine clearance 51-80 mL/min), moderate (creatinine clearance 30-50 mL/min) and severe (creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance.
Croatian: U pojedinaca s blagim oštećenjem bubrežne funkcije (klirens kreatinina 51-80 ml/min) koncentracije apiksabana u plazmi (AUC) povećale su se za 16%, u onih s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30-50 ml/min) za 29%, a u onih s teškim oštećenjem bubrežne funkcije (klirens kreatinina 15-29 ml/min) za 44% u usporedbi s pojedincima s normalnim klirenskom kreatinina.
English: - had a tube (catheter) or an injection into your spinal column (for anaesthesia or pain reduction), your doctor will tell you to take Eliquis 5 hours or more after catheter removal - if you have a prosthetic heart valve - if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned
Croatian: - teška bolest bubrega ili ste na dijalizi - postojeće ili prijašnje jetrene tegobe Eliquis će se primjenjivati uz oprez u bolesnika koji pokazuju znakove poremećaja jetrene funkcije. - ako Vam je u kralježnicu uvedena cjevčica (kateter) ili ste primili injekciju u kralježnicu (za anesteziju ili ublažavanje boli), liječnik će Vam reći da uzmete Eliquis 5 ili više sati nakon izvlačenja katetera - ako imate protetski srčani zalistak - ako liječnik utvrdi da Vam je krvni tlak nestabilan ili je planirano drugačije liječenje ili kirurški postupak za uklanjanje krvnog ugruška iz pluća.
English: Subjects received either apixaban 2.5 mg given orally twice daily (po bid) or enoxaparin 40 mg administered subcutaneously once daily (sc od).
Croatian: Ispitanici su dobivali ili apiksaban u dozi od 2,5 mg peroralno dvaput na dan ili enoksaparin u dozi od 40 mg supkutano jedanput na dan.
English: No changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen.
Croatian: Nakon istodobne primjene apiksabana i naproksena nisu primijećene promjene u učinku naproksena na agregaciju trombocita izazvanu arahidonskom kiselinom niti klinički značajno produljenje vremena krvarenja.
English: Apixaban 2.5 mg po twice daily 12 ± 2 d
Croatian: Apiksaban 2,5 mg p.o. dva puta na dan 12 ± 2 d
English: Major*
Croatian: Značajno*
English: Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window.
Croatian: Kod donošenja odluke o vremenu primjene lijeka, unutar zadanog vremenskog raspona, liječnici mogu uzeti u obzir potencijalne koristi ranije antikoagulantne terapije za profilaksu venskih tromboembolijskih događaja, kao i rizike od krvarenja nakon kirurškog zahvata.
English: The film coated tablets are pink, oval and marked with “894” on one side and “5” on the other side.
Croatian: Ovalne filmom obložene tablete ružičaste boje s oznakom "894" s jedne i "5" s druge strane.
English: Stroke or systemic embolism* 51 (1.62) Stroke Ischaemic or unspecified Haemorrhagic Systemic embolism Stroke, systemic embolism,
Croatian: Moždani udar ili sistemska embolija* Moždani udar Ishemijski ili nespecificiran 43 (1,37) Hemoragijski Sistemska embolija
English: For situations when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, a reversal agent for factor Xa inhibitors is available (see section 4.4).
Croatian: Lijek za reverziju inhibitora faktora Xa dostupan je za situacije kada je potrebna reverzija antikoagulacije zbog krvarenja koje je nekontrolirano ili može ugroziti život (vidjeti dio 4.4).
English: Placebo n (%)
Croatian: Apiksaban 5,0 mg u odnosu na placebo n (%)
English: INFORMATION IN BRAILLE Eliquis 5 mg
Croatian: Eliquis 5 mg
English: INFORMATION IN BRAILLE Eliquis 2.5 mg
Croatian: Eliquis 2,5 mg
English: Reproductive system and breast disorders Abnormal vaginal haemorrhage, urogenital haemorrhage
Croatian: Poremećaji reproduktivnog sustava i dojki Abnormalno vaginalno krvarenje, urogenitalno krvarenje manje često često
English: Respiratory tract haemorrhage
Croatian: Oštećenje jetrene funkcije
English: Rectal haemorrhage, gingival bleeding
Croatian: Rektalno krvarenje, krvarenje iz gingive često često
English: VTEt - No dose adjustment required (see sections 4.4 and 5.2).
Croatian: VTEp - Nije potrebno prilagođavati dozu (vidjeti dijelove 4.4 i 5.2).
English: Enoxaparin 40 mg sc once daily 35 ± 3 d
Croatian: Enoksaparin 40 mg s.c. jedanput na dan 35 ± 3 d
English: For the prevention of stroke and systemic embolism in patients with NVAF, patients with severe renal impairment (creatinine clearance 15-29 mL/min), and patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/L) associated with age ≥ 80 years or body weight ≤ 60 kg should receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2).
Croatian: Za prevenciju moždanog udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija, bolesnici s teškim oštećenjem bubrežne funkcije (klirens kreatinina 15-29 ml/min) i bolesnici u kojih je kreatinin u serumu ≥ 1,5 mg/dl (133 mikromola/l) povezan s dobi ≥ 80 godina ili tjelesnom težinom ≤ 60 kg, trebaju primati manju dozu apiksabana od 2,5 mg dvaput na dan (vidjeti dio 4.2).
English: If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take Eliquis for at least 2 days after your first dose of the medicine containing a vitamin K antagonist.
Croatian: - Prelazak s lijeka Eliquis na antikoagulans koji sadrži antagonist vitamina K (npr. varfarin) Ako Vam liječnik kaže da morate početi uzimati lijek koji sadrži antagonist vitamina K, nastavite uzimati Eliquis još barem 2 dana nakon prve doze lijeka s antagonistom vitamina K. Liječnik Vam mora napraviti krvnu pretragu i reći kada trebate prestati uzimati Eliquis.
English: The major bleeding results for prespecified subgroups including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.
Croatian: Rezultati velikog krvarenja za unaprijed određene podskupine s obzirom na rezultat na ljestvici CHADS2, dob, tjelesnu težinu, spol, status bubrežne funkcije, pretrpljen moždani udar ili tranzitornu ishemijsku ataku i šećernu bolest, bili su u skladu s rezultatima za cjelokupnu populaciju obuhvaćenu ispitivanjem.
English: - for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;
Croatian: - u prevenciji VTE kod elektivnog kirurškog zahvata ugradnje endoproteze kuka ili koljena (VTEp), u liječenju DVT, u liječenju PE i u prevenciji ponavljajućih DVT i PE (VTEt) apiksaban treba primjenjivati uz oprez;
English: Patients with prosthetic heart valves
Croatian: Bolesnici s protetskim srčanim zaliscima
English: The overall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study.
Croatian: U ispitivanju AVERROES ukupna stopa prekida liječenja zbog nuspojava iznosila je 1,5% za apiksaban i 1,3% za ASK.
English: There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 11).
Croatian: + klinički značajnih ali ne velikih krvarenja (CRNM), manjih, i svih krvarenja između skupine koja je liječena apiksabanom u dozi od 2,5 mg dvaput na dan i skupine koja je liječena placebom (vidjeti Tablicu 11).
English: Clarithromycin (500 mg, twice a day), an inhibitor of Pgp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3-fold increase in mean apixaban AUC and Cmax respectively.
Croatian: Klaritromicin (500 mg, dvaput na dan), koji je inhibitor P-gp-a i snažan inhibitor CYP3A4, povećao je srednju vrijednost AUC-a apiksabana 1,6 puta, a vrijednost Cmax 1,3 puta.
English: Apix 2.5 mg vs.
Croatian: BLISTER 2,5 mg
English: The recommended dose is one tablet of Eliquis 2.5 mg twice a day for example, one in the morning and one in the evening.
Croatian: Preporučena doza je jedna tableta lijeka Eliquis 2,5 mg dvaput na dan, primjerice, jedna ujutro i jedna navečer.
English: Interaction with inducers of both CYP3A4 and P-gp The concomitant use of Eliquis with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John's Wort) may lead to a ~50% reduction in apixaban exposure.
Croatian: Istodobna primjena lijeka Eliquis sa snažnim induktorima CYP3A4 i P-gp-a (npr. rifampicinom, fenitoinom, karbamazepinom, fenobarbitalom ili gospinom travom) može smanjiti izlaganje apiksabanu za ~50%.
English: There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 13).
Croatian: + klinički značajnih ali ne velikih krvarenja (CRNM), manjih, i svih krvarenja između skupine koja je liječena apiksabanom u dozi od 2,5 mg dvaput na dan i skupine koja je liječena placebom (vidjeti Tablicu 13).
English: Major VTE
Croatian: Glavni VTE ishodi
English: - They come in blisters in cartons of 14, 20, 28, 56, 60, 168 and 200 film-coated tablets.
Croatian: - Isporučuju se u blisterima u kutijama sa 14, 20, 28, 56, 60, 168 i 200 filmom obloženih tableta.
English: In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 12).
Croatian: U ispitivanju su obje doze apiksabana bile statistički superiorne placebu u primarnom ishodu simptomatskog, ponavljajućeg VTE (nefatalna DVT ili nefatalna PE) ili ukupne smrtnosti (vidjeti Tablicu 12).
English: Bristol-Myers Squibb GmbH & Co. KGaA Tel: 0800 0752002 (+49 (0)89 121 42 350)
Croatian: KGaA Tel: 0800 0752002 (+49 (0)89 121 42 350)
English: The known side effects and how frequently they occur for each of these medical conditions may differ and are listed separately below.For these conditions, the most common general side effect of Eliquis is bleeding which may be potentially life threatening and require immediate medical attention.
Croatian: Poznate nuspojave i njihova učestalost mogu biti različite za svako od tih stanja, pa se u nastavku navode odvojeno za svako pojedinačno stanje.
English: Elderly VTEp and VTEt - No dose adjustment required (see sections 4.4 and 5.2).
Croatian: Starije osobe VTEp i VTEt - nije potrebno prilagođavati dozu (vidjeti dijelove 4.4 i 5.2).
English: After 2 days of coadministration of Eliquis with VKA therapy, an INR should be obtained prior to the next scheduled dose of Eliquis.
Croatian: K treba odrediti INR prije sljedeće planirane doze lijeka Eliquis.
English: Myocardial infarction Vascular Death All-cause death
Croatian: Moždani udar, sistemska embolija, infarkt miokarda ili vaskularna smrt* Infarkt miokarda Vaskularna smrt Ukupna smrtnost
English: • That all patients should be provided with a Patient alert card and be counselled about:
Croatian: • Informaciju o tome da svi bolesnici moraju dobiti Karticu s upozorenjima za bolesnika i da ih se mora posavjetovati o: - Znakovima i simptomima krvarenja te kada moraju potražiti pomoć zdravstvenog radnika - Važnosti pridržavanja plana liječenja
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER 5 mg
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP
English: - They come in blisters in cartons of 10, 20 ,60, 168 and 200 film-coated tablets.
Croatian: - Isporučuju se u blisterima u kutijama sa 10, 20, 60, 168 i 200 filmom obloženih tableta.
English: Table 11: Bleeding Results in the AMPLIFY Study Apixaban N=2,676 n (%)
Croatian: Tablica 11: Rezultati krvarenja u ispitivanju AMPLIFY Apiksaban N=2676 n (%)
English: † Secondary endpoint.
Croatian: † Sekundarna mjera ishoda.
English: In the knee replacement surgery study during the intended treatment period, in the apixaban arm 4 cases of PE were diagnosed against no cases in the enoxaparin arm. No explanation can be given to this higher number of PE.
Croatian: U ispitivanju u kirurškim zahvatima ugradnje endoproteze koljena su tijekom predviđenog razdoblja liječenja u skupini koja je uzimala apiksaban zabilježena 4 slučaja plućne embolije, a u skupini koja je primala enoksaparin niti jedan.
English: Prevention of VTE (VTEp): elective hip or knee replacement surgery The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement.
Croatian: Klinički program za apiksaban osmišljen je kako bi pokazao djelotvornost i sigurnost apiksabana u prevenciji venskih tromboembolijskih događaja u širokom rasponu odraslih bolesnika koji su podvrgnuti elektivnom zahvatu ugradnje endoproteze kuka ili koljena.
English: Recurrent VTE or CVrelated death
Croatian: Ponavljajući VTE ili ukupna smrtnost
English: In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 10).
Croatian: U ispitivanju su obje doze apiksabana bile statistički uspješnije od placeba u primarnom ishodu simptomatskog, ponavljajućeg VTE (nefatalna DVT ili nefatalna PE) ili ukupne smrtnosti (vidjeti Tablicu 10).
English: Skin and subcutaneous tissue disorders Skin rash
Croatian: Poremećaji kože i potkožnog tkiva Kožni osip manje često često
English: The overall incidences of adverse reactions of bleeding, anaemia and abnormalities of transaminases (e.g., ALT levels) were numerically lower in patients on apixaban compared to enoxaparin in the phase II and phase III studies in elective hip and knee replacement surgery.
Croatian: U ispitivanjima faze II i III u elektivnim kirurškim zahvatima ugradnje endoproteze kuka i koljena ukupne incidencije nuspojava krvarenja, anemije i odstupanja od normalnih vrijednosti transaminaza (npr. razine ALT-a) bile su brojčano niže u bolesnika koji su uzimali apiksaban nego u onih koji su primali enoksaparin.
English: Enoxaparin 40 mg sc once daily 12 ± 2 d
Croatian: Enoksaparin 40 mg s.c. jedanput na dan 12 ± 2 d
English: - for the prevention of stroke and systemic embolism in patients with NVAF and serum creatinine ≥ 1.5 mg/dL (133 micromole/L) associated with age ≥ 80 years or body weight ≤ 60 kg, a dose reduction is necessary and described above.
Croatian: - u prevenciji moždanog udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija (NVAF) i serumskim kreatininom ≥ 1,5 mg/dl (133 mikromola/l) povezanim s dobi >80 godina ili tjelesnom težinom ≤ 60 kg, potrebno je smanjenje doze kako je prethodno opisano.
English: Table 9: Bleeding Results in the AMPLIFY Study Apixaban N=2,676 n (%)
Croatian: Tablica 9: Rezultati krvarenja u ispitivanju AMPLIFY Apiksaban N=2676 n (%)
English: - Low blood pressure which may make you feel faint or have a quickened heartbeat - Bleeding: - in your eyes - in your mouth or blood in your spit when coughing
Croatian: Nizak krvni tlak zbog kojega možete imati osjećaj da ćete se onesvijestiti ili Vam srce može početi ubrzano kucati - Mučnina - Krvna slika koja može pokazati: